{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:10:24Z","timestamp":1790511024062,"version":"4.1.0"},"reference-count":47,"publisher":"American Society for Clinical Investigation","issue":"20","funder":[{"name":"NCI","award":["Supported by internal funding,National Cancer Institute,NIH"],"award-info":[{"award-number":["Supported by internal funding,National Cancer Institute,NIH"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,17]]},"abstract":"<jats:p>Meningiomas are the most common adult primary tumor of the central nervous system, but there are no known effective medical therapies for recurrent meningioma, particularly for World Health Organization grade II and III tumors. Meningiomas arise from the meninges, located outside the blood-brain barrier, and therefore may be directly targeted by antibody-mediated immunotherapy. We found that programmed cell death ligand 1 (PD-L1) was highly expressed in multiple human malignant meningioma cell lines and patient tumor samples. PD-L1 was targeted with the anti\u2013PD-L1 antibody avelumab and directed natural killer cells to mediate antibody-dependent cellular cytotoxicity (ADCC) of PD-L1\u2013expressing meningioma tumors both in vitro and in vivo. ADCC of meningioma cells was significantly increased in target cells that upregulated PD-L1 expression and, conversely, abrogated in tumor cells that were depleted of PD-L1. Additionally, the high-affinity natural killer cell line, haNK, outperformed healthy donor NK cells in meningioma ADCC. Together, these data support a clinical trial designed to target PD-L1 with avelumab and haNK cells, potentially offering a novel immunotherapeutic approach for patients with malignant meningioma.<\/jats:p>","DOI":"10.1172\/jci.insight.130688","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T12:02:09Z","timestamp":1568894529000},"source":"Crossref","is-referenced-by-count":57,"title":["Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK"],"prefix":"10.1172","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-1825","authenticated-orcid":true,"given":"Amber J.","family":"Giles","sequence":"first","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Hao","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."},{"name":"Neurosurgical Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Padget","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lynes","sequence":"additional","affiliation":[{"name":"Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8359-6246","authenticated-orcid":true,"given":"Jinkyu","family":"Jung","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Cao","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Fujii","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Utah, Salt Lake City, Utah, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-0262","authenticated-orcid":true,"given":"David","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Utah, Salt Lake City, Utah, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9882-0899","authenticated-orcid":true,"given":"Edjah K.","family":"Nduom","sequence":"additional","affiliation":[{"name":"Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-0867","authenticated-orcid":true,"given":"Chunzhang","family":"Yang","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Lee","sequence":"additional","affiliation":[{"name":"NantKwest, Culver City, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4682-8298","authenticated-orcid":true,"given":"Patrick","family":"Soon-Shiong","sequence":"additional","affiliation":[{"name":"NantKwest, Culver City, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-3154","authenticated-orcid":true,"given":"James W.","family":"Hodge","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deric M.","family":"Park","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."},{"name":"Department of Neurology and the Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou223"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000330399.55586.63"},{"key":"B3","article-title":"Long term surgical outcome and prognostic factors of atypical and malignant meningiomas","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.121582"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2014.11.022"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3171\/2010.1.JNS091114"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.35"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9761"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30239-5"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30240-1"},{"issue":"23","key":"B14","doi-asserted-by":"crossref","first-page":"33498","DOI":"10.18632\/oncotarget.9256","article-title":"Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab","volume":"7","author":"Fujii","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0463"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8957"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26527"},{"issue":"4","key":"B22","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"issue":"11","key":"B23","first-page":"2859","article-title":"Antileukemia activity of a natural killer cell line against human leukemias","volume":"4","author":"Yan","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"7","key":"B24","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.18632\/oncotarget.3082","article-title":"Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma","volume":"6","author":"Du","year":"2015","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2018.08.023"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1259"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.209"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00051","article-title":"Overcoming resistance to natural killer cell based immunotherapies for solid tumors","volume":"9","author":"Nayyar","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"B31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30077"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2013.789874"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/320941","article-title":"Blood brain barrier: a challenge for effectual therapy of brain tumors","volume":"2015","author":"Bhowmik","year":"2015","journal-title":"Biomed Res Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4303"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"issue":"29","key":"B38","doi-asserted-by":"crossref","first-page":"46756","DOI":"10.18632\/oncotarget.18606","article-title":"Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping","volume":"8","author":"Jesinghaus","year":"2017","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04023-x"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1417"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/1758834015615514"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0220-y","article-title":"Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody","volume":"5","author":"Donahue","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3015"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031"},{"key":"B46","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"NPJ Genom Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30767"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/130688\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:22:39Z","timestamp":1779193359000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/130688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":47,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2019,10,17]]},"published-print":{"date-parts":[[2019,10,17]]}},"alternative-id":["10.1172\/jci.insight.130688"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.130688","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"article-number":"e130688"}}